Biocon pact with Amylin for diabetes drug making

Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs, said a press release from the company. Research will center on Amylin’s ‘phybrid’ technology.  Under the terms of the Development and Commercialisation Agreement, Amylin will provide expertise in peptide hormone development, particularly in the area of phybrid technology, as well as metabolic disease therapeutics.